Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Smolle, E; Taucher, V; Pichler, M; Petru, E; Lax, S; Haybaeck, J.
Targeting signaling pathways in epithelial ovarian cancer.
Int J Mol Sci. 2013; 14(5):9536-9555
Doi: 10.3390/ijms14059536
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Haybäck Johannes
- Taucher Elisabeth Marie
- Co-Autor*innen der Med Uni Graz
- Petru Edgar
- Pichler Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Ovarian carcinoma (OC) is the most lethal gynecological malignancy. Response to platinum-based chemotherapy is poor in some patients and, thus, current research is focusing on new therapy options. The various histological types of OC are characterized by distinctive molecular genetic alterations that are relevant for ovarian tumorigenesis. The understanding of these molecular pathways is essential for the development of novel therapeutic strategies. We want to give an overview on the molecular genetic changes of the histopathological types of OC and their role as putative therapeutic targets. In Depth Review of Existing Data: In 2012, the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, was approved for OC treatment. Bevacizumab has shown promising results as single agent and in combination with conventional chemotherapy, but its target is not distinctive when analyzed before treatment. At present, mammalian target of rapamycin (mTOR) inhibitors, poly-ADP-ribose polymerase (PARP) inhibitors and components of the EGFR pathway are in the focus of clinical research. Interestingly, some phytochemical substances show good synergistic effects when used in combination with chemotherapy. Ongoing studies of targeted agents in conjunction with chemotherapy will show whether there are alternative options to bevacizumab available for OC patients. Novel targets which can be assessed before therapy to predict efficacy are needed. The assessment of therapeutic targets is continuously improved by molecular pathological analyses on tumor tissue. A careful selection of patients for personalized treatment will help to reduce putative side effects and toxicity.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Biomarkers, Tumor - metabolism
- Diagnostic Imaging -
- Female -
- Humans -
- Molecular Targeted Therapy -
- Neoplasms, Glandular and Epithelial - diagnosis
- Ovarian Neoplasms - diagnosis
- Signal Transduction -
- Find related publications in this database (Keywords)
- ovarian cancer
- molecular carcinogenesis
- targeted therapy